Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
national top stories
alnylam pharmaceuticals
amgen
biotech
boston blog main
boston top stories
cholesterol
clinical study
clinical trials
data
disease
enzyme
gag
gene editing
genome editing
hunter syndrome
ids
inclisiran
mps ii
mucopolysaccharidosis ii
new york
new york blog main
new york top stories
pcsk9 inhibitors
praluent
regeneron pharmaceuticals
repatha
san francisco
san francisco blog main
san francisco top stories
sandy macrae
sangamo therapeutics
studies
the medicines co.
zinc finger nucleases
What
morning
2
×
phase
2
×
benefit
bringing
cholesterol
clears
closer
drug
editing
fda
filing
gene
going
humans
inched
isn't
landmark
little
lowering
market
medco
medicine
medicines
nasdaq
positive
preps
reported
reports
result
results
sangamo
study
tests
therapeutics
touting
trial
twice
u.s
yearly
Language
unset
Current search:
morning
×
phase
×
@xconomy.com
4 years ago
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
@xconomy.com
5 years ago
In Landmark Gene-Editing Study, Sangamo Reports Little Benefit